Q2 2024 EPS Estimates for Adaptimmune Therapeutics plc Decreased by Analyst (NASDAQ:ADAP)

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Free Report) – Leerink Partnrs cut their Q2 2024 EPS estimates for shares of Adaptimmune Therapeutics in a research report issued on Wednesday, May 15th. Leerink Partnrs analyst J. Chang now forecasts that the biotechnology company will post earnings of ($0.17) per share for the quarter, down from their previous […]

Related Keywords

United Kingdom , United States , Leerink Partnrs , Employer Solutions Trustee Ltd , Capital Partners , Nasdaq , Adaptimmune Therapeutics Company Profile , Key Client Fiduciary Advisors , Columbia Advisory Partners , Adaptimmune Therapeutics , Free Report , Adaptimmune Therapeutic , Get Free Report , Hill Capital Management , Solutions Trustee Ltd , Advisory Partners , Focus Capital Partners , Client Fiduciary Advisors , Adaptimmune Therapeutics Daily ,